CareLit Fachartikel
Antitumor efficacy of the c-met inhibitor tivantinib (ARQ–197) in liver cancer cells: effects on apoptosis and cell cycle
S Lü, A Rizzani, FT Kolligs, B Göke, A Gerbes, EN De Toni · Zeitschrift für Gastroenterologie · 2012 · Heft 01
Dokument
1109841
CareLit-ID
Jahr
2012
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
Background: c-met has become a promising therapeutic target in cancer therapy due to its prognostic significance and its important role in determining the metastatic properties of solid tumors. Tivantinib (ARQ–197) is a novel selective small molecule inhibitor of c-Met which is undergoing clinical investigation in several tumor entities.Aims and methods: we explored the effects of tivantinib on hepatocellular carcinoma cell lines to determine its mechanisms of action. Huh7 and HepG2 HCC cell lines were incubated with increasing concentrations of tivantinib or vehicle. For viability experiments pico-green assays…
Schlagworte
HCC
c-met
Apoptosis
After
Caspase 3
Caspase 8
Antibodies
Tumor
Zeitschrift für Gastroenterologie
